Overview

Refralon Versus Amiodarone for Cardioversion of Paroxysmal Fibrillation and Atrial Flutter

Status:
Recruiting
Trial end date:
2024-03-30
Target enrollment:
Participant gender:
Summary
Patients hospitalized with paroxysmal atrial fibrillation and flutter to restore sinus rhythm will be randomized into two groups: one will be cardioversion with refralon and the other with amiodarone
Phase:
N/A
Details
Lead Sponsor:
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Treatments:
Amiodarone